Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Antioxidant Response of Chronic Wounds to Hyperbaric Oxygen Therapy

  • Antoni Sureda,

    Affiliation Research Group on Community Nutrition and Oxidative Stress, University of Balearic Islands, and CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122, Palma de Mallorca, Balearic Islands, Spain

  • Juan M. Batle,

    Affiliation Research Group on Community Nutrition and Oxidative Stress, University of Balearic Islands, and CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122, Palma de Mallorca, Balearic Islands, Spain

  • Miquel Martorell,

    Affiliations Research Group on Community Nutrition and Oxidative Stress, University of Balearic Islands, and CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122, Palma de Mallorca, Balearic Islands, Spain, Departamento de Nutrición y Dietética, Facultad de Farmacia, Universidad de Concepción, E-4070386, Concepción, Chile

  • Xavier Capó,

    Affiliation Research Group on Community Nutrition and Oxidative Stress, University of Balearic Islands, and CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122, Palma de Mallorca, Balearic Islands, Spain

  • Silvia Tejada,

    Affiliation Experimental Laboratory, Research Unit, Son Llàtzer Hospital, IUNICS, Ctra. Manacor km 4, E-07198, Palma de Mallorca, Balearic Islands, Spain

  • Josep A. Tur,

    Affiliation Research Group on Community Nutrition and Oxidative Stress, University of Balearic Islands, and CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122, Palma de Mallorca, Balearic Islands, Spain

  • Antoni Pons

    Affiliation Research Group on Community Nutrition and Oxidative Stress, University of Balearic Islands, and CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122, Palma de Mallorca, Balearic Islands, Spain

Antioxidant Response of Chronic Wounds to Hyperbaric Oxygen Therapy

  • Antoni Sureda, 
  • Juan M. Batle, 
  • Miquel Martorell, 
  • Xavier Capó, 
  • Silvia Tejada, 
  • Josep A. Tur, 
  • Antoni Pons


We analyzed the effects of the clinical hyperbaric oxygen therapy (HBOT) on the plasma antioxidant response and levels of endothelin-1, Interleukine-6 (IL-6) and vascular endothelial growth factor (VEGF) in patients with chronic wounds (20.2±10.0 months without healing). They received 20 HBOT sessions (five sessions/week), and blood samples were obtained at sessions 1, 5 and 20 before and 2 hours after the HBOT. An additional blood sample was collected 1 month after wound recovery. Serum creatine kinase activity decreased progressively in accordance with the wound healing. Plasma catalase activity significantly increased after the first and fifth sessions of HBOT. Plasma myeloperoxidase activity reported significantly lower values after sessions. Plasma VEGF and IL-6 increased after sessions. Endothelin-1 levels were progressively decreasing during the HBOT, being significant at the session 20. Plasma malondialdehyde concentration was significantly reduced at the last session. Both creatine kinase activity and malondialdehyde levels were maintained lower 1 month after wound recovery respect to initial values. In conclusion, HBOT enhanced the plasma antioxidant defenses and may contribute to activate the healing resolution, angiogenesis and vascular tone regulation by increasing the VEGF and IL-6 release and the endothelin-1 decrease, which may be significant factors in stimulating wound healing.


Hyperbaric oxygen therapy (HBOT) is the clinical utilization of the oxygen at pressures higher than atmospheric pressure, habitually at 2–3 atmosphere absolute (ATA) pressure with 100% oxygen exposure. Breathing oxygen at elevated pressure increases the oxygen availability for the body tissues. Moreover, HBOT increases the capacity of blood plasma to transport oxygen with respect to normobaric conditions. HBOT has been successfully employed to manage diverse clinical diseases [1], such as non-healing diabetic and selected problem wounds, and necrotizing soft tissue infection. The wound healing is a complex process and requires an orderly and coordinated sequence of steps involving the production and participation of many growth factors, components of the extracellular matrix, and several cell types. Tissue repair involves the mobilization and activation of the immune system that is responsible for the clearance of the damaged tissue from dead cells and matrix debris, and for the mediators synthesis that stimulates angiogenesis and fibroblast growth [2]. The repair process includes an inflammatory phase, but also a resolution phase of the inflammation and wound healing returning to tissue homeostasis [2, 3].

The main basis behind the use of HBOT in the management of chronic non-healing wounds is the increase in the amount of oxygen in blood and the generation of a favourable gradient for the diffusion of oxygen into the affected tissues. In most of the pathological situations with delayed wound healing, there is a direct association with the harmful effects of prolonged oxygen deficit [4]. In this way, diverse processes essential for normal wound healing such as fibroblast proliferation, angiogenesis, collagen deposition or resistance to infection are oxygen-dependent [5]. The increase of oxygen levels in the hypoxic wound is essential for the cells involved in the healing process (neutrophils, fibroblasts, macrophages) to carry out their specific repair functions [6]. Linked to this observation, HBOT has been evidenced to diminish the number of major lower limb amputations among diabetic people [7, 8]. The increased oxygen availability during HBOT is an essential mediating factor associated to wound collagen deposition, cross-linking and neovascularization [9]. HBOT is not able to increase the quantity of oxygen bound to hemoglobin molecules, but can raise the quantity of dissolved oxygen in the plasma [10]. Moreover, the increased oxygen availability increases ROS generation which is directly associated with the modulation of the inflammatory process [1113]. HBOT increases the expression of diverse growth factors and activates the hypoxia-inducible factor 1 (HIF-1) that may enhance angiogenesis and fibroblast proliferation [14, 15]. In addition, most authors have indicated that the resulting hyperoxia may cause vasoconstriction, thereby decreasing tissue oedema [8, 16], although this oedema decrease might be cause by an inflammation reduction after HBOT [17]. HBOT treatment also induces changes in the oxidative capabilities of immune cells, which can actively participate in the process of wound healing [18]. Further significant effects of HBOT associated to wound healing are an enhanced capacity to kill bacteria by leukocytes, suppression of bacterial proliferation due to its bactericidal effect on anaerobes and microaerophilic aerobes, down-regulation of inflammatory pathways by reducing the expression of pro-inflammatory cytokines, and prevention of leukocyte activation after an ischemic reperfusion [11, 19, 20].

HBOT exposure can increase the production of reactive oxygen species (ROS), directly related to the amount of oxygen present. ROS overproduction is detrimental for cells because it can damage cell components including proteins, lipids, and nucleic acids leading to significant alteration of health status [21]. However, a moderate increase in ROS can be beneficial because ROS may also act as cellular messengers in many signal transduction pathways [22]. Accordingly, vascular endothelial growth factor (VEGF) is up-regulated when cells are exposed to both hypoxic and hyperoxic conditions, whereas endothelin-1 seems to be decreased after a depth dive which is related to the hyperoxia condition [23]. VEGF is considered a key promoter of the angiogenic process which is essential for the maintenance of the integrity of blood vessels, while endothelin-1 participates in the maintenance of the basal vascular tone and blood pressure by activating the vascular smooth muscle. In addition, endothelin-1 together with other proteins operate in a network that promotes myofibroblast differentiation and persistence during wound repair [24]. Acute production of IL-6 has direct anti-inflammatory effects or stimulates immune cell production of anti-inflammatory components, such as the IL-1-receptor antagonist and IL-10 [25]. IL-6 treatment of wound enhances healing by switching immune cells to resolution of inflammation [26]. In addition, IL-6 has been reported to enhance mesenchymal stem cells proliferation in order to protect from apoptosis and to increase the rate of in vitro wound healing [27].

The aim of this study was to define the time course of various changes in response to HBOT in chronic wounded patients in which conventional treatments have been reported to be ineffective. Specifically, the activities of antioxidant enzymes were measured in erythrocytes and plasma as well as plasma myeloperoxidase activity and malondialdehyde adducts. Moreover, plasma levels of endothelin-1, VEGF and IL-6 were determined.

Materials and Methods

Patient characteristics

14 patients, ten men and four women, (65.8 ± 5.8 years old) presenting a chronic non-healing wound situation were recruited and volunteered to participate in the study. The protocol procedures were designed in compliance with the recommendations for clinical research of the Declaration of Helsinki and were revised and approved by the Ethical Committee of Clinical Investigation of the Government of Balearic Islands (Palma de Mallorca, Balearic Islands, Spain) with number IB1295/09PI. At the beginning of the study, 18 patients were recruited but two decided to abandon before the finishing all sessions because they suffered from claustrophobia and another two were excluded due to health complications: one reported ear pain during the first HBOT and the second one suffered a bowel obstruction secondary to radiation enteritis. All the participants were informed about the research protocol before giving their written consent to participate in the study. Seven of the subjects suffered from diabetic foot ulcer, four of them from osteomyelitis, two from enteritis radica and one from osteoarthritis. Previous conventional treatments, included topical antibiotics (selected after bacterial culture and antibiotic sensitivity tests), topical dressings, and debridement of tissue, reported to be ineffective in this kind of patients. In the case of osteomyelitis, which is an infectious process, antibiotics were supplied systemically and topically. All participants were non-smokers and did not take any antioxidant dietary supplement for 1 month before the study. Before beginning the HBOT, all participants passed a standard medical and physical revision at the hospital. During the HBOT, wounds were cleaned with saline solution, treated with antibiotics, and daily wound curettage or debridement of necrotic tissue was performed to get a well-bleeding granulating base.

Experimental procedure

The protocol procedure consisted of 20 HBOT exposures in a hyperbaric chamber during a month (five sessions/week form Monday to Friday). Patients breathed 100% oxygen at a pressure of 2.2 ATA in the hyperbaric chamber during 1 h.

Blood samples were obtained before and 2 hours after the first, the fifth and the twentieth HBOT sessions. In addition, another blood sample was collected 1 month after ending HBOT with wound recovery and was utilized as control sample for routine analysis plus plasma malondialdehyde (MDA) levels, as an indicator of lipid peroxidation. Venous blood samples were collected from the antecubital vein of patients in appropriate vacutainers. Hematological parameters including blood cell counts, hematocrit and hemoglobin concentration were determined using an automatic flow cytometer analyzer Technicon H2 (Bayer) VCS system following the standard clinical procedures. Creatine kinase (CK) was measured in serum by standard procedures using an autoanalyser (Technicon DAX System).

Plasma was obtained after centrifugation of the blood samples at 900g at 4°C for 30 min. The plasma phase was removed, and the erythrocytes at the bottom were washed with phosphate buffered saline and centrifuged again at 900g for 30 min. Erythrocytes were lysed with distilled water and reconstituted in the same volume as the initial plasma volume. Erythrocytes and plasma were immediately stored at -80°C until use. Biochemical procedures were carried out in duplicate.

Antioxidant enzyme activities

Superoxide dismutase (SOD) and catalase (CAT) activities were measured in erythrocytes and plasma, glutathione peroxidase (GPx) and glutathione reductase (GR) activities were determined in erythrocytes, and myeloperoxidase (MPO) activity was determined in plasma by methods previously described [28]. CAT activity was determined by a spectrophotometric method based on the decomposition of H2O2. SOD activity was determined using a xanthine/xanthine oxidase system to produce the superoxide anion. The produced anion induces the reduction of cytochrome C, which was monitored at 550 nm. GPx activity was determined by an assay that requires H2O2 and NADPH as substrates and GR as enzyme indicator. The decrease in NADPH absorbance was followed at 340 nm during the oxidation of NADPH to NADP+. GR activity determines the rate of conversion of oxidized glutathione (GSSG) to reduced glutathione (GSH) by monitoring the oxidation of NADPH at 340 nm. MPO activity was measured following the oxidation of guaiacol. The reaction mixture contained 13.5 mM guaiacol and the reaction was initiated with 300 μM H2O2, and the absorbance at 470 nm was monitored. All enzymatic activities were determined at 37°C in a spectrophotometer Shimadzu UV-2100.

MDA-protein adducts

The levels of plasma MDA-protein adducts were measured by an enzyme immunoassay (Cell Biolabs, Inc.). Briefly, protein samples or standards (10 μg mL-1) were adsorbed onto a 96-well plate and incubated overnight at 4°C. MDA–protein adducts were visualized with a specific anti-MDA antibody, followed by an HRP-conjugated secondary antibody. The concentration of MDA-protein adducts in the samples was calculated using a standard curve of known concentrations.

Nitrite determination

Nitrite levels were determined in plasma by the acidic Griess reaction using a spectrophotometric method. Plasma was deproteinized with acetone and kept overnight at -20°C. Samples were centrifuged at 15,000g for 10 min at 4°C, and supernatants were recovered. A 96-well plate was loaded with the samples or nitrite standard solutions in duplicate. Sulfanilamide in 5% HCl and N-(1-napthyl)-ethylenediamine (0.1% w/v) in water was then added to each well. The absorbance at 540 nm was measured following an incubation of 30 min.

VEGF and endothelin-1 immunoassay

Quantification of VEGF and endothelin-1 in plasma was performed using a commercially available immunoassay kits (Assay Designs, Inc., Ann Arbor, MI) following the manual instructions. All determinations were realized in duplicate, and absorbance was measured using a microplate reader at 450 nm.

IL-6 determination

Plasma IL-6 was determined using an ELISA kit (Diaclone, lit for GENPROBE) following the manufacturer’s instructions for use. The overall intra-assay coefficient of variation was calculated to be 4.4% for IL-6; the calculated overall inter-assay coefficient of variation was 9.1% for IL-6.

Statistical analysis

Statistical analysis was performed using Statistical Package for Social Sciences (SPSS version17.0). Data are expressed as mean ± SEM and considering p < 0.05 statistically significant. To assess the normal distribution of the data the Kolmogorov–Smirnov test was applied. The statistical differences between the obtained data were evaluated by two-way analysis of variance (ANOVA). The analyzed factors were the HBOT (HBOT), the number of the session (T) and their possible interaction (Int). When significant differences were reported, a post hoc testing (DMS) was used to establish the differences between the different data. Student’s t-test for paired data was used for hematological parameters, CK activity and MDA levels before the first session and 1 month after wound recovery.


Previous conventional treatments to heal the chronic wounds (including antibiotics, topical dressings, and debridement of tissue) were ineffective in these patients. The patients presented wounds with an average time without symptoms of healing of 20.2±10.0 months when they began with the HBOT. All patients participating in the present study were recovered after 20 HBOT sessions. The diabetic wound recovery in the patients’ foot before the first HBOT session was observed, being this recovery higher after the last HBOT session. The statistical analysis addressed to determine if there were differences between the diabetic and non-diabetic patients reported no significant differences in any of the parameters studied (data not shown).

Changes in hematological parameters, serum CK activity and MDA concentration in samples from wounded patients obtained before and after the sessions 1, 5 and 20 of the HBO treatment are shown in Table 1. Significant statistical effects were not evidenced in any on the hematological parameters analyzed. The duration of HBOT significantly influenced serum CK activity with a progressive decrease along the sessions. The results at the session 5 were significantly lower than the ones from the first session and the results from the session 20 were also lower than the ones found in the sessions 1 and 5; finally, at the session 20, serum CK activity attained a 54% reduction with respect to the session 1 (initial value). Similarly, the plasma concentration of MDA adducts was significantly influenced by the treatment duration; plasma MDA was significantly reduced at the last session with respect to the session 1 (p < 0.05). In addition, the hematological parameters did not report any significant differences between the data before the first treatment and 1 month after wound healing. On the contrary, CK activity and MDA adducts were significantly lower 1 month after wound recovery respect to initial values.

Table 1. Hematological parameters, creatine kinase activity and MDA in samples obtained from wounded patients (n = 14) before and after the sessions 1, 5 and 20 of the HBO treatment and 1 month after wound recovery.

Erythrocyte enzymatic activities are reported in Fig 1. No significant effects of HBOT and treatment duration on erythrocyte antioxidant activities were observed. The initial antioxidant enzymatic activities of erythrocytes were maintained after each HBOT session and along the treatment.

Fig 1. Erythrocyte enzyme activities obtained from wounded patients (n = 14) before and after the sessions 1, 5 and 20 of the HBO treatment.

One way ANOVA, P < 0.05, * indicates significant differences between samples obtained before and after HBO treatment.

Plasma enzymatic activities are reported in Fig 2. Plasma SOD activity was not influenced by HBOT and treatment duration with similar values in all situations. Plasma catalase activity responded to the HBOT, but not to the duration of the treatment, with a significant raise after the sessions 1 and 5 (p < 0.05), although this increase was not significant after 20 HBOT sessions. A significant reduction of plasma MPO activity was evidenced after each analyzed HBOT sessions while duration treatment did not affect it.

Fig 2. Plasma enzyme activities obtained from wounded patients (n = 14) before and after the sessions 1, 5 and 20 of the HBO treatment.

One way ANOVA, P < 0.05, * indicates significant differences between samples obtained before HBO treatment and after HBO treatment.

Plasma VEGF, endothelin-1 and IL-6 levels are presented in Fig 3. VEGF and IL-6 levels reported a significant increase after each HBOT session respect to the pre-session values (p < 0.05), without differences between the basal values of session 1, 5 and 20. A progressive decrease in endothelin-1 levels were observed during the HBOT, although statistical differences were only evidenced at the session 20 with respect to the session 1 (p < 0.05). Plasma nitrite levels as a marker of the NO synthesis, a blood pressure modulator remained unchanged during all the HBOT.

Fig 3. Plasma nitrite, VEGF, endothelin-1 and IL-6 levels.

Nitrite, VEGF, endothelin-1 and IL-6 results in plasma obtained from wounded patients (n = 14) before and after the sessions 1, 5 and 20 of the HBO treatment. One way ANOVA, P < 0.05, * indicates significant differences between samples obtained before HBO treatment and after HBO treatment, # indicates significant differences respect to the session 1.


The patients included in this study had infections and/or venous or arterial insufficiency with long-standing wounds lasting for mean of 20.2 ± 10 months, without having experienced any improvement. In the present study, the HBOT for 1 month (20 HBOT sessions) has showed to induce considerable decreases in the wound size and fast healing rates similar to previous studies [11]. Patients with chronic wounds have high values of oxidative and tissue damage markers including MDA levels and CK activity respect reference values and the values determined one month after the wound healing [29, 30]. The decrease observed in the oxidative damage markers during HBOT is in accordance with the recovery process reported in the patients. In this way, it has been reported that the subjects with first myocardial infarction which received thrombolytic therapy alone evidenced a higher peak of CK activity respect to a HBOT group [31]. However, some studies have showed small changes in markers of lipid peroxidation in plasma after HBOT [32, 33]. In a prior study performed with healthy subjects, HBOT did not induce alterations in markers of oxidative damage in plasma and lymphocytes, but it induced an antioxidant response characterized by an increased lymphocyte GPx activity and hemoxygenase-1 (HO-1) mRNA levels, which participates in a inflammatory pro-resolving circuit [34]. In addition, no significant effect by HBOT and treatment duration was evidenced in hematological parameters and erythrocyte antioxidant enzymes, in agreement with previous results [32, 35].

The therapeutic basis behind HBOT is the increase in the quantity of dissolved oxygen carried by the blood leading to a significant increase in oxygen concentration in the tissues of the body. High oxygen concentration could increase reactive oxygen species (ROS) production; but paradoxically HBOT induces an antioxidant environment in plasma by increasing the plasma catalase activity. Diverse studies have evidenced increases in the total plasma antioxidant capacity determined after a session with HBOT [3638]. Moreover, it has also shown that HBOT may operate as a hormetic agent via activating antioxidant and cytoprotective genes in order to protect against a stressful situation [39]. The increase of ROS levels could mediate the expression of key molecules of inflammation, resolution and wound repair. In this way, this increase can be considered the primary mechanism of action for HBOT in wound healing [40]. HBOT could increase ROS generation, inducing a protective and adaptative response to help cells and tissues to manage different endogenous and environmental stressors more efficiently. The increased production of ROS after HBOT activates the nuclear factor κβ (NFκβ) which up-regulates several pathways involved in the initiation of the protective mechanisms [41]. At sites of neovascularization, ROS stimulate growth factor synthesis by enhancing synthesis and stabilizing HIF-1 [40]. Plasma MPO activity significantly decreased after each HBOT session throughout the experimental period. The observed decrease in the plasma MPO activity could be indicative of a reduced activation of neutrophils. It has been reported that hyperbaric oxygen exposure at 3 ATA for 45 min prevents leukocyte adherence mediated by B2 integrins, protecting tissues from injury, although it did not reduce neutrophil viability and functions in response to chemoattractants [42, 43]. Moreover, reductions in the blood supply in wounded tissues can alter the mitochondrial electron transport chain increasing electron leakage and consequently increasing ROS production [44, 45]. HBOT induces the ROS production which can act as signals mediating physiologic responses in mitochondria. HBOT preserves mitochondrial integrity via maintenance of mitochondrial membrane potential and reduction of the mitochondrial pathway of apoptosis [46]. In accordance, repetitive sessions of HBOT could induce adaptations to the oxidative machinery of neutrophils in order to decrease the responsiveness against stimulus, diminishing the inflammatory response and improving the recovery process in the damaged tissues. In this sense, HBOT sessions promote an anti-inflammatory response similar to the resolution inflammatory response by lipid mediators including resolvins and several cytokines [3]. Resolvins exert strong anti-inflammatory effects by blunting excessive neutrophil infiltration into tissues and decreasing the production of pro-inflammatory mediators [3, 47]. Diabetic patients have an altered wound healing which is attributed to diabetic impairment of wound healing resolution phase, even it is pointed out that stimulation of the resolution phase with pro-resolving lipid mediators as resolvins could be a new approach to treat chronic, non-healing wounds in diabetic patients [47]. IL-6 is a pleiotropic cytokine with pro-inflammatory and anti-inflammatory functions [48]. In response to an acute infection, trauma or exercise, acute elevations of IL-6 mediate anti-inflammatory effects, whereas chronic elevated levels of IL-6 are associated with pathogenic inflammation and with detrimental effects on metabolism [49]. IL-6 has been reported to play a role in the resolution of inflammation and to achieve a satisfactory wound healing [26]. IL-6 enhances the induction of macrophages by an alternatively pathway, which are characterized by their anti-inflammatory and wound healing capability [26]. HBOT treatment increased IL-6 plasma levels, which in turn could promote alternative activated macrophages in the wounded tissue driving to the resolution phase of healing wounds. The repetitive sessions of HBOT produced repetitive inputs of IL-6 that participated in the wound healing.

VEGF is an important angiogenic factor with a great growth-stimulatory effect on endothelial cells, and also with a potent mediator effects on vascular permeability [50]. HBOT results in a moderate ROS production, which can induce the release of VEGF and consequently can promote angiogenesis [51]. The ROS, produced during wound healing, may participate as signaling molecules that regulate the VEGF production and diverse cellular responses. HBOT induces VEGF expression which in turn stimulates angiogenesis and improves the recovery process. In a study with human umbilical vein endothelial cell model, it was reported a significant induction in the VEGF gene expression after HBOT [52]. However, only few studies are performed in humans to analyze the effects of HBOT on plasma VEGF concentration, and the results found are controversial [53, 54], possibly as a consequence of different HBOT, experimental procedure, and the different type of wounds evaluated. The release of nitric oxide by smooth muscle cells has been indicated to be involved in the signaling cascade that leads to VEGF synthesis and release [55]. In subjects reporting wounds favorably affected by HBOT, an increase in the levels of nitric oxide was observed after HBOT [9]. Nevertheless, although the nitrite levels obtained in the present study tend to increase 2 hours after each HBOT session, no significant changes were reported. It can be suggested that nitric oxide levels early peaked after the HBOT session and consequently, the measured nitrite returned to background levels after 2 hours.

Endothelin-1 is a strongly vasoconstrictive factor produced by vascular endothelial cells playing a central function in the regulation of basal vascular tone [56]. Endothelin-1 evidenced significant lower values after 20 sessions of HBOT than the initial values. These decreased levels could be necessary to maintain an adequate vascular tone after HBOT and to increase the vascular blood flow in order to facilitate the oxygen availability to wounded tissues. Nitric oxide was reported to effectively suppress the release and the physiological action of endothelin-1 and to nitrosylate endothelin receptors reducing the affinity for endothelin-1 [57]. Consequently, and in addition to its direct vasodilator effects, nitric oxide can indirectly induce vasodilation by inhibiting the release of endothelin-1 [58].

The reduced number of cases in our study and the different varieties of wound etiologies could be a limitation; however, since this is a plasma study, the central responses to HBOT may not depend on the wound type. The loss of patients throughout the study is another limitation arising from the occurrence of complications or abandonment of the protocol for its long duration. Controlled studies with larger number of patients are required for further analysis. In conclusion, HBOT may improve the healing process in chronic wounds. HBOT is a potential therapeutic tool to treat chronic non-healing wounds derived from pathological conditions compromising blood supply and tissue oxygen availability. Although a variety of wound types was included in the current study, the healing wound after HBOT was achieved. The present data evidenced that HBOT regulates wound healing by a common mechanism to several pathologies that includes a plasmatic antioxidant response, the induction of an angiogenic response, the regulation of vascular tone, and switching to resolution of inflammation via increasing the release of IL-6. However, more strong investigations with a greater number of patients and HBOT non-treated patients as control group are necessary so as to increase the understanding of the molecular and beneficial effects of HBOT in the treatment of chronic wounds.

Supporting Information

S1 Tables. Tables including the presented data.



The study was supported by the Spanish Ministry of Health and Consumption Affairs (Programme of Promotion of Biomedical Research and Health Sciences, Projects 05/1276, 08/1259, and 11/01791, Red Predimed-RETIC RD06/0045/1004, and CIBEROBN CB12/03/30038), Grants of support to research groups no. 35/2011 and 23/2012 (Balearic Islands Gov. and EU FEDER funds).

Author Contributions

  1. Conceptualization: AS JMB JAT AP.
  2. Formal analysis: AS.
  3. Funding acquisition: JAT AP.
  4. Investigation: AS JMB MM XC.
  5. Methodology: AS JMB JAT AP.
  6. Project administration: AS AP.
  7. Resources: AS JMB AP.
  8. Software: AS ST.
  9. Writing – original draft: AS ST.
  10. Writing – review & editing: AS MM XC ST JAT AP.


  1. 1. Thackham JA, McElwain DL, Long RJ. The use of hyperbaric oxygen therapy to treat chronic wounds: A review. Wound Repair Regen. 2008; 16(3):321–30. pmid:18471250
  2. 2. Frangogiannis NG. The immune system and the remodeling infarcted heart: cell biological insights and therapeutic opportunities. J Cardiovasc Pharmacol. 2014; 63(3):185–95. pmid:24072174
  3. 3. Serhan CN, Chiang N, Dalli J. The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin Immunol. 2015.
  4. 4. Tandara AA, Mustoe TA. Oxygen in wound healing—more than a nutrient. World J Surg. 2004; 28(3):294–300. pmid:14961188
  5. 5. Warriner RA 3rd, Hopf HW. The effect of hyperbaric oxygen in the enhancement of healing in selected problem wounds. Undersea Hyperb Med. 2012; 39(5):923–35. pmid:23045921
  6. 6. Shah JB. Correction of Hypoxia, a Critical Element for Wound Bed Preparation Guidelines: TIMEO2 Principle of Wound Bed Preparation. J Am Col Certif Wound Spec. 2011; 3(2):26–32. pmid:24527166
  7. 7. Game FL, Hinchliffe RJ, Apelqvist J, Armstrong DG, Bakker K, Hartemann A, et al. A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev. 2012; 28 Suppl 1:119–41. pmid:22271737
  8. 8. Stoekenbroek RM, Santema TB, Legemate DA, Ubbink DT, van den Brink A, Koelemay MJ. Hyperbaric oxygen for the treatment of diabetic foot ulcers: a systematic review. Eur J Vasc Endovasc Surg. 2014; 47(6):647–55. pmid:24726143
  9. 9. Boykin JV Jr., C. Baylis Hyperbaric oxygen therapy mediates increased nitric oxide production associated with wound healing: a preliminary study. Adv Skin Wound Care. 2007; 20(7):382–8. pmid:17620739
  10. 10. Sheffield PJ. Measuring tissue oxygen tension: a review. Undersea Hyperb Med. 1998; 25(3):179–88. pmid:9789339
  11. 11. Kendall AC, Whatmore JL, Harries LW, Winyard PG, Smerdon GR, Eggleton P. Changes in inflammatory gene expression induced by hyperbaric oxygen treatment in human endothelial cells under chronic wound conditions. Exp Cell Res. 2012; 318(3):207–16. pmid:22063471
  12. 12. Kendall AC, Whatmore JL, Winyard PG, Smerdon GR, Eggleton P. Hyperbaric oxygen treatment reduces neutrophil-endothelial adhesion in chronic wound conditions through S-nitrosation. Wound Repair Regen. 2013; 21(6):860–8. pmid:24134224
  13. 13. Zhang Q, Chang Q, Cox RA, Gong X, Gould LJ. Hyperbaric oxygen attenuates apoptosis and decreases inflammation in an ischemic wound model. J Invest Dermatol. 2008; 128(8):2102–12. pmid:18337831
  14. 14. Sheikh AY, Rollins MD, Hopf HW, Hunt TK. Hyperoxia improves microvascular perfusion in a murine wound model. Wound Repair Regen. 2005; 13(3):303–8. pmid:15953050
  15. 15. Sunkari VG, Lind F, Botusan IR, Kashif A, Liu ZJ, Yla-Herttuala S, et al. Hyperbaric oxygen therapy activates hypoxia-inducible factor 1 (HIF-1), which contributes to improved wound healing in diabetic mice. Wound Repair Regen. 2015; 23(1):98–103. pmid:25532619
  16. 16. Garcia-Covarrubias L, Cuauhtemoc Sanchez-Rodriguez E. [Hyperbaric oxygenation therapy, basic concepts]. Gac Med Mex. 2000; 136(1):45–56. pmid:10721602
  17. 17. Yildirim AO, Eryilmaz M, Kaldirim U, Eyi YE, Tuncer SK, Eroglu M, et al. Effectiveness of hyperbaric oxygen and ozone applications in tissue healing in generated soft tissue trauma model in rats: an experimental study. Ulus Travma Acil Cerrahi Derg. 2014; 20(3):167–75. pmid:24936837
  18. 18. Zgheib C, Xu J, Liechty KW. Targeting Inflammatory Cytokines and Extracellular Matrix Composition to Promote Wound Regeneration. Adv Wound Care (New Rochelle). 2014; 3(4):344–55.
  19. 19. Barnes RC. Point: hyperbaric oxygen is beneficial for diabetic foot wounds. Clin Infect Dis. 2006; 43(2):188–92. pmid:16779745
  20. 20. Aydin F, Kaya A, Savran A, Incesu M, Karakuzu C, Ozturk AM. Diabetic hand infections and hyperbaric oxygen therapy. Acta Orthop Traumatol Turc. 2014; 48(6):649–54. pmid:25637729
  21. 21. Wells PG, McCallum GP, Chen CS, Henderson JT, Lee CJ, Perstin J, et al. Oxidative stress in developmental origins of disease: teratogenesis, neurodevelopmental deficits, and cancer. Toxicol Sci. 2009; 108(1):4–18. pmid:19126598
  22. 22. Thom SR. Oxidative stress is fundamental to hyperbaric oxygen therapy. J Appl Physiol. 2009; 106:988–95. pmid:18845776
  23. 23. Gole Y, Gargne O, Coulange M, Steinberg JG, Bouhaddi M, Jammes Y, et al. Hyperoxia-induced alterations in cardiovascular function and autonomic control during return to normoxic breathing. Eur J Appl Physiol. 2011; 111:937–46. pmid:21069379
  24. 24. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res. 2010; 106(11):1675–80. pmid:20538689
  25. 25. Walsh NP, Gleeson M, Shephard RJ, Woods JA, Bishop NC, Fleshner M, et al. Position statement. Part one: Immune function and exercise. Exerc Immunol Rev. 2011; 17:6–63. pmid:21446352
  26. 26. Fernando MR, Reyes JL, Iannuzzi J, Leung G, McKay DM. The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages. PLoS One. 2014; 9(4):e94188. pmid:24736635
  27. 27. Pricola KL, Kuhn NZ, Haleem-Smith H, Song Y, Tuan RS. Interleukin-6 maintains bone marrow-derived mesenchymal stem cell stemness by an ERK1/2-dependent mechanism. J Cell Biochem. 2009; 108(3):577–88. pmid:19650110
  28. 28. Sureda A, Batle JM, Tauler P, Aguilo A, Cases N, Tur JA, et al. Hypoxia/reoxygenation and vitamin C intake influence NO synthesis and antioxidant defenses of neutrophils. Free Radic Biol Med. 2004; 37(11):1744–55. pmid:15528034
  29. 29. Cervellin G, Comelli I, Lippi G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med. 2010; 48(6):749–56. pmid:20298139
  30. 30. Ma L, Li P, Shi Z, Hou T, Chen X, Du J. A prospective, randomized, controlled study of hyperbaric oxygen therapy: effects on healing and oxidative stress of ulcer tissue in patients with a diabetic foot ulcer. Ostomy Wound Manage. 2013; 59(3):18–24. pmid:23475448
  31. 31. Dekleva M, Neskovic A, Vlahovic A, Putnikovic B, Beleslin B, Ostojic M. Adjunctive effect of hyperbaric oxygen treatment after thrombolysis on left ventricular function in patients with acute myocardial infarction. Am Heart J. 2004; 148(4):E14. pmid:15459609
  32. 32. Gasier HG, Fothergill DM. Oxidative stress, antioxidant defenses and nitric oxide production following hyperoxic exposures. Undersea Hyperb Med. 2013; 40(2):125–34. pmid:23682544
  33. 33. Gurdol F, Cimsit M, Oner-Iyidogan Y, Korpinar S, Yalcinkaya S, Kocak H. Early and late effects of hyperbaric oxygen treatment on oxidative stress parameters in diabetic patients. Physiol Res. 2008; 57(1):41–7. pmid:17223730
  34. 34. Chiang N, Shinohara M, Dalli J, Mirakaj V, Kibi M, Choi AM, et al. Inhaled carbon monoxide accelerates resolution of inflammation via unique proresolving mediator-heme oxygenase-1 circuits. J Immunol. 2013; 190(12):6378–88. pmid:23650615
  35. 35. Handy RD, Bryson P, Moody AJ, Handy LM, Sneyd JR. Oxidative metabolism in platelets, platelet aggregation, and hematology in patients undergoing multiple hyperbaric oxygen exposures. Undersea Hyperb Med. 2005; 32(5):327–40. pmid:16457082
  36. 36. Labrouche S, Javorschi S, Leroy D, Gbikpi-Benissan G, Freyburger G. Influence of hyperbaric oxygen on leukocyte functions and haemostasis in normal volunteer divers. Thromb Res. 1999; 96(4):309–15. pmid:10593434
  37. 37. Sureda A, Ferrer MD, Batle JM, Tauler P, Tur JA, Pons A. Scuba diving increases erythrocyte and plasma antioxidant defenses and spares NO without oxidative damage. Medicine and Science in Sports and Exercise. 2009; 41:1271–6. pmid:19461538
  38. 38. Goudable J, Delafosse B, Viale JP. Acute effects of hyperbaric hyperoxic exposures on lipid peroxidation and total oxidant capacity. Clin Nutr. 1996; 15(Suppl 1):10.
  39. 39. Godman CA, Joshi R, Giardina C, Perdrizet G, Hightower LE. Hyperbaric oxygen treatment induces antioxidant gene expression. Ann N Y Acad Sci. 2010; 1197:178–83. pmid:20536847
  40. 40. Thom SR. Oxidative stress is fundamental to hyperbaric oxygen therapy. J Appl Physiol (1985). 2009; 106(3):988–95.
  41. 41. Vince RV, Midgley AW, Laden G, Madden LA. The effect of hyperbaric oxygen preconditioning on heat shock protein 72 expression following in vitro stress in human monocytes. Cell Stress Chaperones. 2011; 16(3):339–43. pmid:21132545
  42. 42. Chen Q, Banick PD, Thom SR. Functional inhibition of rat polymorphonuclear leukocyte B2 integrins by hyperbaric oxygen is associated with impaired cGMP synthesis. J Pharmacol Exp Ther. 1996; 276(3):929–33. pmid:8786572
  43. 43. Juttner B, Scheinichen D, Bartsch S, Heine J, Ruschulte H, Elsner HA, et al. Lack of toxic side effects in neutrophils following hyperbaric oxygen. Undersea Hyperb Med. 2003; 30(4):305–11. pmid:14756233
  44. 44. Chen Q, Moghaddas S, Hoppel CL, Lesnefsky EJ. Reversible blockade of electron transport during ischemia protects mitochondria and decreases myocardial injury following reperfusion. J Pharmacol Exp Ther. 2006; 319(3):1405–12. pmid:16990510
  45. 45. Kalogeris T, Bao Y, Korthuis RJ. Mitochondrial reactive oxygen species: a double edged sword in ischemia/reperfusion vs preconditioning. Redox Biol. 2014; 2:702–14. pmid:24944913
  46. 46. Palzur E, Zaaroor M, Vlodavsky E, Milman F, Soustiel JF. Neuroprotective effect of hyperbaric oxygen therapy in brain injury is mediated by preservation of mitochondrial membrane properties. Brain Res. 2008; 1221:126–33. pmid:18561900
  47. 47. Tang Y, Zhang MJ, Hellmann J, Kosuri M, Bhatnagar A, Spite M. Proresolution therapy for the treatment of delayed healing of diabetic wounds. Diabetes. 2013; 62(2):618–27. pmid:23043160
  48. 48. Kuhn KA, Manieri NA, Liu TC, Stappenbeck TS. IL-6 stimulates intestinal epithelial proliferation and repair after injury. PLoS One. 2014; 9(12):e114195. pmid:25478789
  49. 49. Fontes JA, Rose NR, Cihakova D. The varying faces of IL-6: From cardiac protection to cardiac failure. Cytokine. 2015; 74(1):62–8. pmid:25649043
  50. 50. Gordillo GM, Roy S, Khanna S, Schlanger R, Khandelwal S, Phillips G, et al. Topical oxygen therapy induces vascular endothelial growth factor expression and improves closure of clinically presented chronic wounds. Clin Exp Pharm Physiol 2008; 35:957–64.
  51. 51. Luo JD, Chen AF. Nitric oxide: a newly discovered function on wound healing. Acta Pharmacol. 2005; 26:259–64.
  52. 52. Lee CC, Chen SC, Tsai SC, Wang BW, Liu YC, Lee HM, et al. Hyperbaric oxygen induces VEGF expression through ERK, JNK and c-Jun/AP-1 activation in human umbilical vein endothelial cells. J Biomed Sci. 2006; 13(1):143–56. pmid:16328781
  53. 53. Wang CJ, Ko JY, Kuo YR, Yang YJ. Molecular changes in diabetic foot ulcers. Diabetes Res Clin Pract. 2011; 94(1):105–10. pmid:21742400
  54. 54. Jung S, Wermker K, Poetschik H, Ziebura T, Kleinheinz J. The impact of hyperbaric oxygen therapy on serological values of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). Head Face Med. 2010; 6:29. pmid:21176170
  55. 55. Zachary I, Gliki G. Signaling transduction mechanism mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 2001; 49:568–81. pmid:11166270
  56. 56. Alonso D, Radomski MW. Nitric oxide, platelet function, myocardial infarction and reperfusion therapies. Heart Fail Rev. 2003; 8(1):47–54. pmid:12652159
  57. 57. Bescos R, Ferrer-Roca V, Galilea P, Roig A, Drobnic F, Sureda A, et al. Sodium nitrate supplementation does not enhance performance of endurance athletes. Med Sci Sports Exerc. 2012; 4(12):2400–9.
  58. 58. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov. 2008; 7:156–67. pmid:18167491